Analysts at Lifesci Capital initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) in a research note issued to investors on Monday, MarketBeat reports. The brokerage set an “outperform” rating and a $41.00 price target on the stock. Lifesci Capital’s price target suggests a potential upside of 54.89% from the company’s previous close.
Several other research firms also recently commented on ORKA. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Wedbush started coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price target for the company. Finally, TD Cowen started coverage on shares of Oruka Therapeutics in a research report on Monday. They issued a “buy” rating for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $41.25.
Check Out Our Latest Stock Report on Oruka Therapeutics
Oruka Therapeutics Stock Performance
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Read More
- Five stocks we like better than Oruka Therapeutics
- Investing in Commodities: What Are They? How to Invest in Them
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What is the FTSE 100 index?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.